Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.
Department of Neurology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, South Korea.
J Neurol Sci. 2017 Nov 15;382:36-39. doi: 10.1016/j.jns.2017.09.019. Epub 2017 Sep 18.
Negative myoclonus is a jerky, brief, and sudden interruption of voluntary muscle contraction. Although gabapentin and pregabalin have been reported to induce positive myoclonus in some patients with impaired renal function, there are only a few studies describing pregabalin- or gabapentin-induced negative myoclonus. This study reviewed patients who had developed pregabalin- or gabapentin-induced negative myoclonus.
We collected the patients with negative myoclonus who were referred to the department of neurology at a university-affiliated hospital and selected pregabalin- or gabapentin-induced negative myoclonus. Then reviewed the literature with respect to pregabalin- or gabapentin-induced negative myoclonus.
A total of 77 patients with negative myoclonus were reviewed. Among them, 21 neuropathic pain patients who were prescribed and developed negative myoclonus induced by pregabalin (9 cases) or gabapentin (12 cases). To prove causality of the drug, probable and certain level of category according to the WHO-UMC criteria were recruited. Of the 21 patients, 3 had impaired renal function, while 18 had normal renal function. Review of the literature identified 7 further cases (6 had normal renal function) with pregabalin- or gabapentin-induced negative myoclonus.
Pregabalin- and gabapentin-induced negative myoclonus can develop even in patients with normal renal function. Physicians should keep in mind the possibility of patients developing negative myoclonus under treatment of pregabalin or gabapentin even in short period of time and with low dosage, and in the normal range of renal function. Further prospective study investigating incidence and risk factors is warranted.
负性肌阵挛是一种短暂而急促的随意肌收缩中断。虽然加巴喷丁和普瑞巴林在一些肾功能受损的患者中已被报道可引起正性肌阵挛,但仅有少数研究描述了普瑞巴林或加巴喷丁引起的负性肌阵挛。本研究回顾了出现普瑞巴林或加巴喷丁引起的负性肌阵挛的患者。
我们收集了到大学附属医院神经内科就诊的出现负性肌阵挛的患者,并选择了由普瑞巴林或加巴喷丁引起的负性肌阵挛。然后对普瑞巴林或加巴喷丁引起的负性肌阵挛的文献进行了复习。
共回顾了 77 例负性肌阵挛患者。其中,21 例为神经病理性疼痛患者,服用普瑞巴林(9 例)或加巴喷丁(12 例)后出现负性肌阵挛。为了证明药物的因果关系,我们根据世界卫生组织-药物不良反应监测中心(WHO-UMC)标准招募了可能和很可能级别的病例。在 21 例患者中,有 3 例肾功能受损,18 例肾功能正常。文献复习还发现了另外 7 例(6 例肾功能正常)由普瑞巴林或加巴喷丁引起的负性肌阵挛。
即使在肾功能正常的患者中,也可能出现普瑞巴林和加巴喷丁引起的负性肌阵挛。即使在短时间内和低剂量以及在正常肾功能范围内,医生也应牢记患者在接受加巴喷丁或普瑞巴林治疗时出现负性肌阵挛的可能性。有必要进行进一步的前瞻性研究,以调查其发生率和风险因素。